PT-141 Side Effects: The FDA Label Numbers, Explained

Short answer: PT-141 has something no other compound in this catalog has: a complete, FDA-reviewed safety file. The label numbers are real and worth knowing — nausea 40.0%, flushing 20.3%, injection-site reactions 13.2%, headache 11.3% — mostly transient and dose-related, with one cardiovascular caution the label handles explicitly.

Most pages answering this query paraphrase the label vaguely and then quietly imply the numbers apply to whatever they're selling. This page does the opposite: exact figures, the 52-week follow-up, and the honest line between the studied injectable drug and the unstudied strip. Compound background lives in our PT-141 guide.

The most documented safety file in the catalog

Every other peptide in this lineup asks you to weigh thin literature and user reports. PT-141 — as bremelanotide (brand name Vyleesi) — went through the full FDA gauntlet: pooled phase 3 trials in 627 patients, a 52-week extension study, and an approval on June 21, 2019 for one narrowly defined prescription indication in premenopausal women [published human data — injectable drug label].

That matters for a safety reader. You are not guessing with this molecule — you're reading the same document a prescribing physician reads. Nothing else in the catalog offers that.

The phase 3 numbers, exactly

From the label (NDA 210557, pooled phase 3, n=627 on drug versus placebo):

• Nausea: 40.0% (vs 1.3% on placebo) — the dominant effect by a wide margin
• Flushing: 20.3%
• Injection-site reactions: 13.2%
• Headache: 11.3%
• Vomiting: 4.8%

[published human data — injectable drug label] Two honest readings of that nausea figure, both true: it's common — two in five trial participants — and it's the label's most common reason for discontinuation. It's also described as dose-related and temporary, and it happened under full-bioavailability injection on a fixed dosing schedule. Common, known, and predictable is a very different thing from unknown.

What 52 weeks of follow-up showed

The core trials (the RECONNECT studies, Kingsberg et al., Obstetrics & Gynecology 2019 — PMID 31599840) were followed by a 52-week open-label extension (Simon et al., same journal — PMID 31599847). Over that longer window, drug-related adverse events tracked the same pattern: nausea 40.4%, flushing 20.6%, headache 12.0% [published human data].

The consistency is genuinely good news for a buyer: the profile didn't drift or worsen across a year of use. What you see in the label is what the molecule does — stable, characterized, documented.

The one caution to take seriously

Beyond the nuisance effects, the label carries a hemodynamic warning: bremelanotide can cause transient increases in blood pressure and decreases in heart rate after dosing, and it's contraindicated in uncontrolled hypertension or known cardiovascular disease [published human data — injectable drug label].

That contraindication is not fine print — it's the safety gate around this entire molecule, and it's exactly why this category belongs in a conversation with a licensed provider before anything else. The broader landscape of who should approach which categories carefully is covered in our peptide contraindications guide.

The honesty passage

One bounded passage, stated plainly: everything above describes the subcutaneous auto-injector drug in controlled trials — and no published safety data exists for PT-141 as a sublingual strip, so the strip's profile is unmeasured in both directions. You cannot assume the injectable's 40% nausea rate applies to a strip (unstudied), and you cannot assume a strip avoids it (equally unstudied). Separately, the catalog product is a three-active blend whose COA verifies two of the three actives. That's the complete caveat — and it doesn't erase the fact that this molecule, uniquely here, has a real safety file to reason from. Our sublingual PT-141 page covers the delivery-route question, and PT-141 vs Viagra covers how the mechanism differs from the vascular drugs.

How it's sold here

The InstaMed PT-141+ strip is a three-active blend (PT-141 1 mg + Oxytocin 25 mcg + Aminophenpyrrole 20 mg, 10-count, Mint) sold at open checkout — order on the PT-141+ page.

The bottom line

PT-141 is the best-documented safety story in the catalog — full stop. A published phase 3 program, a stable year-long tolerability profile, and a label that names its one serious caution out loud. The strip format carries the usual unstudied-format asterisk, but no other molecule here lets you start the conversation with actual FDA-reviewed numbers. Before anything in this category, talk with a licensed provider — especially if blood pressure or cardiovascular history is anywhere in your picture — and bring the injectable's label to that conversation.

---

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

This content is for educational purposes only and is not medical advice. Consult a licensed healthcare provider before starting any new product. Individual results vary.